Spyre Therapeutics prices offering of 4,117,648 shares at $85 for about $350 million

Spyre Therapeutics priced an underwritten public offering of 4,117,648 common shares at USD 85.00 each, expecting about USD 350 million gross proceeds. Underwriters have a 30-day option for up to about USD 52.5 million more. Closing targeted for Oct. 7, 2026, subject to customary conditions.